Published in the San Diego Union-Tribune, insightful discussions and detailed descriptions of how the ImmunityBio COVID-19 vaccine research led by Dr. Patrick Soon-Shiong, M.D. Chairman and CEO of NantWorks, and founder and MOX owner, is different from other vaccine candidates.
Why? Targeting both the nucleocapsid protein on the interior of the virus particle and the spike protein on the virus’ surface will potentially lead to long-term immunity to the SARS-CoV-2 virus.
